AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVEN)
- Registry ID
- CRTH258C2302
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2019-10-22
- Last update
- 2019-06-06
Conditions
- CENTRAL RETINAL VEIN OCCLUSION
- MACULAR EDEMA
Related clinical trials
- A PHASE III, MULTI¿CENTER, RANDOMIZED, DOUBLE¿MASKED, SHAM¿CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
- AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION (RAPTOR)
- TREATMENT FOR CENTRAL-INVOLVED DIABETIC MACULAR EDEMA IN EYES WITH VERY GOOD VISUAL ACUITY
- A 12-MONTH, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DRIVEN MACULAR EDEMA (ME).
View on source registry